Understanding health regulatory authorities in Latin America is essential for manufacturers of medical devices, pharmaceuticals, food supplements, cosmetics, sanitizers, and veterinary products, planning market access in Latam. The region offers strong commercial potential but operates under distinct national regulatory frameworks requiring careful navigation.
In this article, we focus specifically on the countries where Mandala International already operates in Latin America: Brazil, Mexico, Colombia, and Peru. These four markets represent the core of our regional expertise and account for most regulatory opportunities for international health product manufacturers.
There is no unified regulatory system in Latam. Each country has its own competent authority, classification logic, documentation standards, and compliance expectations. Market access must therefore be designed country by country, with a structured and informed regulatory strategy.
Why understanding regulatory authorities in LATAM is critical
Latin America is strengthening its regulatory oversight. Authorities are increasing technical scrutiny, reinforcing post-market surveillance, and modernizing digital submission systems. These evolutions create opportunities for well-prepared manufacturers and risks for those entering without a clear plan.
An incorrect product classification can significantly delay approval. A misaligned regulatory strategy can increase costs and extend timelines. A weak understanding of local representation rules can compromise long-term commercial control. Regulatory preparation is not a formality! It is a strategic investment that directly impacts time to market and scalability.
Brazil: The most structured and demanding system in this region
Brazil is the largest healthcare market in Latin America. It is also one of the most technically demanding from a regulatory perspective. The country operates under a highly structured legal framework and applies detailed technical review processes.
1. ANVISA for health product regulation
The primary authority responsible for health products is Agência Nacional de Vigilância Sanitária. ANVISA regulates medical devices, pharmaceuticals, food supplements, cosmetics, and sanitizing products under a risk-based classification system.
Medical devices are categorized according to risk, and the level of documentation increases accordingly. Higher-risk devices require comprehensive technical files and often local Good Manufacturing Practices (GMP) certification. Pharmaceutical registration demands extensive quality, safety, and efficacy data, and review timelines can be substantial depending on the product type.
Foreign manufacturers cannot directly hold registrations in Brazil. A Brazilian legal entity must act as the registration holder and interface with the authority. This structural requirement has significant commercial implications and must be carefully planned.
2. MAPA for veterinary products
Veterinary medicines and certain animal-related products fall under the authority of Ministério da Agricultura e Pecuária. MAPA operates under an agricultural regulatory framework that differs from ANVISA’s health product system.
The procedures, technical standards, and inspection requirements follow specific agricultural legislation. Companies entering the Brazilian veterinary market must therefore adapt to a distinct regulatory logic that requires dedicated expertise.
Brazil rewards thorough preparation. It penalizes improvisation.
Mexico: A strategic and structured regulatory environment
Mexico represents a key gateway between North America and Latin America. Its regulatory system is mature and increasingly aligned with international standards, while maintaining national specificities.
COFEPRIS and federal oversight
The competent authority in Mexico is Comisión Federal para la Protección contra Riesgos Sanitarios. COFEPRIS oversees medical devices, pharmaceuticals, food supplements, and cosmetics through a centralized federal framework.
The authority applies a risk-based classification approach to medical devices and has established reliance mechanisms in certain cases. These mechanisms can facilitate evaluation when products already hold approvals from recognized reference countries. However, documentation must always comply with Mexican standards and labeling requirements are strictly enforced.
A local registration holder is mandatory. All submissions must be in Spanish. Product claims must be carefully validated, as classification may shift depending on the file’s intended use.
Mexico can offer efficiency when the regulatory strategy is precise. Ambiguity, however, can lead to reclassification or formal objections.
Colombia: A distinct model with direct manufacturer ownership
Colombia has positioned itself as a stable and increasingly attractive healthcare market. Its regulatory authority has reinforced procedural clarity and structured review mechanisms.
INVIMA and registration framework
Health products in Colombia are regulated by Instituto Nacional de Vigilancia de Medicamentos y Alimentos. INVIMA oversees pharmaceuticals, medical devices, food supplements, cosmetics, and selected food categories under a centralized system.
Among the four countries covered in this guide, Colombia is the only one where the foreign manufacturer can remain the direct holder of its registrations. Unlike Brazil, Mexico, and Peru, no local entity is required to own the sanitary registration. The manufacturer remains the official registration holder, in a structure comparable to the European model.
A local legal representative is still mandatory to interface with the authority and ensure regulatory communication. This model provides greater commercial independence and long-term control over market strategy.
The authority operates with defined registration pathways and established documentation standards. In certain situations, international certifications can support the evaluation process, but local compliance remains mandatory. Technical files must follow Colombian formats, and administrative precision is essential.
Post-market obligations are actively monitored. Variations, renewals, and product modifications must be managed with discipline. Regulatory approval is not the final step; lifecycle compliance is equally critical.
Colombia combines procedural structure with commercial opportunity for manufacturers.
Peru: An agile but evolving regulatory landscape
Peru is often considered an accessible entry point into Latin America. Its regulatory authority has modernized procedures, but the framework continues to evolve through frequent regulatory updates.
DIGEMID and sanitary registration
The authority responsible for medicines and medical devices is Dirección General de Medicamentos, Insumos y Drogas. DIGEMID manages product registrations under a national sanitary control system.
Registration timelines can be shorter than in Brazil, particularly for certain product categories. However, regulatory reforms occur regularly, and companies must stay informed about new resolutions and technical adjustments. A proactive monitoring approach is necessary to avoid unexpected compliance gaps.
As in other Latam countries, a local legal entity must hold the registration. Documentation and labeling must strictly comply with national standards.
Peru offers flexibility, but regulatory accuracy remains essential.
Key differences and the trend toward regulatory harmonization
Brazil, Mexico, Colombia, and Peru operate independently in the management of their health product registrations. Each authority conducts its own evaluation and applies its own interpretation of classification, documentation depth, and compliance requirements.
However, the regional and international trend is moving toward greater harmonization. Health authorities are progressively aligning technical requirements with international standards. Partial recognition mechanisms, reliance models, and inter-agency cooperation agreements are being implemented to simplify and accelerate marketing authorization procedures in specific contexts.
These developments do not eliminate national requirements, but they can create strategic opportunities when properly anticipated. A regulatory pathway designed in isolation may overlook simplification programs or recognition frameworks that could reduce timelines and duplication of effort.
For this reason, regulatory planning should not be approached country by country in isolation, but rather as part of a coordinated regional strategy aligned with the manufacturer’s global expansion plan. Working with a partner capable of analyzing cross-border regulatory interactions can help identify optimization opportunities while maintaining full compliance.
Building secure and scalable market access in Latam
Health regulatory authorities in Latin America are increasingly rigorous and technically structured. At the same time, the region remains one of the most dynamic growth areas for health product manufacturers.
Success requires anticipation, technical expertise, and local presence. It also requires a partner who understands not only the regulatory texts but also the operational expectations of each authority.
Mandala International operates directly in Brazil, Mexico, Colombia, and Peru. Our teams coordinate regulatory positioning, local representation, and long-term compliance management across these markets to structure efficient and scalable market access strategies.
TALK TO AN EXPERT
Expanding Latin America starts with identifying the correct regulatory authority and defining the right country-specific pathway. Our team will help you structure a compliant and scalable regulatory strategy across Brazil, Mexico, Colombia, and Peru.
By submitting this form, you agree to be contacted by Mandala International and to receive related communications.
